Results 321 to 330 of about 5,633,974 (393)
Some of the next articles are maybe not open access.

Enzyme Inhibitors

Medicinal chemistry, 2021
A. K. Ganguly, Sesha Sridevi Alluri
openaire   +2 more sources

Evolution of Molecularly Imprinted Enzyme Inhibitors: From Simple Activity Inhibition to Pathological Cell Regulation.

Angewandte Chemie, 2021
Molecular imprinting represents one of the most promising strategies to design artificial enzyme inhibitors. However, the study of molecularly imprinted enzyme inhibitors (MIEIs) remains at a primary stage.
Jingjing Xu   +5 more
semanticscholar   +1 more source

COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?

Journal of the American Medical Association (JAMA), 2020
Coronavirus disease 2019 (COVID-19) is a current pandemic infection caused by a positive-sense RNA virus named the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The particularly infectious capacity of the virus, along with mortality rates
Ankit B. Patel, A. Verma
semanticscholar   +1 more source

Aminoalkylated Phenolic Chalcones: Investigation of Biological Effects on Acetylcholinesterase and Carbonic Anhydrase I and II as Potential Lead Enzyme Inhibitors

Letters in Drug Design & Discovery, 2020
Phenolic Mannich bases have been reported as acetylcholinesterase (AChE) inhibitors for the medication of Alzheimer's disease. Carbonic Anhydrases (CAs) are molecular targets for anticonvulsant, diuretic and antiglaucoma drugs in the clinic.
C. Yamali   +4 more
semanticscholar   +1 more source

Enzyme Inhibitors

Principles of Enzymology for the Food Sciences, 2018
John R. Whitaker
openaire   +2 more sources

Advances in Discovering Deubiquitinating Enzyme (DUB) Inhibitors.

Journal of Medicinal Chemistry, 2020
Deubiquitinating enzymes, or DUBs, comprise a family of proteases that regulate ubiquitination dynamics. Since their discovery in the 1980s, genetic and functional studies have nominated DUBs as a promising class for drug discovery across diverse ...
N. Schauer   +4 more
semanticscholar   +1 more source

[Angiotensin-converting enzyme inhibitors].

Recenti progressi in medicina, 1991
The introduction of angiotensin-converting enzyme (ACE) inhibitors for the treatment of hypertension and heart failure is probably the most important advance in cardiovascular pharmacotherapy in the last few decades. Although the role of the renin-angiotensin system (RAS) in cardiovascular diseases had been investigated extensively for more than 70 yr,
Irene Gavras, Haralambos Gavras
openaire   +4 more sources

Angiotensin-converting enzyme inhibitors

Critical Care Nurse, 1990
This review focuses on the use of angiotensin converting enzyme (ACE) inhibitors in hypertensive diseases. Specifically discussed are: proposed mechanisms of action, the pharmacology of the commercially available ACE inhibitors (captopril, enalapril, and lisinopril), their renal effects, and their safety and efficacy.
B L, Herlihy, J T, Herlihy
openaire   +4 more sources

Inhibitors of glyoxalase enzymes

Biochemical and Biophysical Research Communications, 1980
Abstract Both glyoxalase enzymes from various sources are inhibited by nucleotides, nucleosides and a series of structurally related compounds in an apparently cooperative manner. In general, aromatic compounds, which contain heterocyclic nitrogen and/or have amino groups on the aromatic ring, are effective inhibitors of these enzymes.
B, Oray, S J, Norton
openaire   +2 more sources

Angiotensin-converting enzyme inhibitors

2001
Publisher Summary Angiotensin-converting enzyme (ACE) inhibitors were first studied clinically in the 1970s. ACE inhibitors were discovered by taking advantage of previous basic research on the physiology of sodium, potassium, and water homeostasis and blood pressure regulation, in a reciprocal way ACE have also advanced research in this field, and ...
J, Menard, A A, Patchett
openaire   +2 more sources

Home - About - Disclaimer - Privacy